Latest Reimbursement News

OncoSil Medical secures $8 million in capital to fund a pivotal German government-sponsored clinical trial and accelerate its European commercial expansion.

Memphasys has lodged regulatory submissions for its Felix™ System in Australia and India, following CE Mark approval, while progressing UK market entry under the CE Mark transition framework.

Aroa Biosurgery’s latest business update reveals promising clinical outcomes from its Myriad trauma study and evolving reimbursement policies that could reshape its market position. The company also projects solid revenue growth for FY26, supported by strategic commercial initiatives.

Aroa Biosurgery reaffirms strong FY26 guidance, buoyed by favourable US Medicare reimbursement for Symphony and promising trauma study results for Myriad.

Cyclopharm has reported a record $32.3 million in operating revenue for FY2025, led by explosive growth in its U.S. Technegas market following FDA approval. The company reaffirms its ambitious target of 250–300 U.S. installations by mid-2026 amid strong clinical momentum.

Emyria Limited reports that approximately 67% of patients treated for PTSD remain in remission over 12 months post-treatment, highlighting the potential for lasting recovery and cost-effective care.

Pure Foods Tasmania has reported a profitable quarter with improved margins and strategic growth moves, including a new contract packing deal and the acquisition of premium ice cream brand Elato.

Iceni Gold Limited reported a busy December quarter focused on advancing diamond drilling at its 14 Mile Well and Welcome Creek projects in Western Australia, with assay results expected soon and a cash position of $1.53 million.

333D Ltd reports continued revenue growth in digital asset management and unveils a pioneering blockchain solution for MRI data storage, reinforcing its foothold in digital healthcare.

Tissue Repair’s December quarter update reveals a cautious path forward for its Phase 3 TR987 trial amid slow patient recruitment, while its TR Pro+ product line gains momentum through a new distributor partnership and upcoming product launches.

Adherium Limited has exceeded its 2025 shipment goals for its Hailie Smartinhaler devices, driven by rapid growth in remote patient monitoring activations and improved US Medicare reimbursement policies.

Hydrocarbon Dynamics Limited has entered voluntary suspension pending a major transaction announcement while continuing global trials of its Multi-Flow product. A new auditor appointment and board leadership change mark a period of strategic transition.